Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A research study in children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day Ended

2023-506830-66-00 SGA - small for gestational age children 2019-05-29
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep… Ended

2023-508681-15-00 Adult focal (partial onset) epilepsy 2019-05-28
EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou… Ended

2023-509216-28-00 Generalized Pustular Psoriasis 2019-05-27
A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended

2023-506733-30-00 Multiple Myeloma relapsed and/or refractory 2019-05-16
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Localised unresectable adenocarcinoma or squamous cell 2019-05-13
Medical-scientific research into a new own skin graft product (EHSG-KF) Ended

2024-512190-27-00 Adults and children with full thickness skin defects 2019-05-13
Therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations Ended

2024-514823-41-00 Chronic Lymphocytic Leukemia (CLL) 2019-04-29
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis Ended

2024-519288-17-00 High-risk Non-muscle Invasive Bladder Cancer 2019-04-26
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended

2024-511781-37-00 YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE 2019-04-16
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 2019-04-09
Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients Ended

2023-508081-15-00 High-risk B-cell acute lymphoblastic leukemia 2019-04-04
A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Ended

2023-506009-20-00 Spinal Muscular Atrophy (SMA) 2019-03-29
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell … Ended

2023-507902-15-00 Non-Small Cell Lung Cancer 2019-03-26
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 oligometastatic hormone sensitive prostate cancer 2019-03-21
Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended

2024-515352-20-00 myelodysplastic syndrome with IDH1 mutated 2019-03-20
A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended

2024-510985-17-00 First Line Treatment in Subjects with Claudin 18.2 (CLD 2019-03-14
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended

2023-509834-20-00 untreated FLT3-mutated Acute Myeloid Leukemia 2019-03-13
A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended

2024-512585-34-00 Indolent Systemic Mastocytosis (ISM) 2019-02-27
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended

2023-503812-34-00 Locally Advanced or Metastatic Disease in Solid Tumors 2019-02-13
study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended

2024-513858-29-01 myelodysplastic syndrome with IDH2 mutated 2019-02-06
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients… Ended

2024-516844-25-01 Patients with ras-mutated metastatIc colorectal cancer 2019-01-03
An Open-Label Phase 2 study to evaluate the effect of PT2977 for the treatment of von Hippel-Lindau Disease-Associated with kidney cancer Ended

2023-509119-99-00 Von Hippel-Lindau disease-associated Renal Cell Carcino 2019-01-02
Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase… Ended

2023-509044-96-00 Resectabel gastric and gastroesophageal junction adenoc 2018-12-21
A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM… Ended

2024-517417-32-00 CHRONIC MYELOID LEUKEMIA 2018-11-22